Day: August 12, 2021

Expanded installed base and booked initial revenue for Proteograph Product Suite REDWOOD CITY, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2021. “I am incredibly proud of our team and the strides we are making to transform proteomics and empower the scientific community,” said Omid Farokhzad, Chair and Chief Executive Officer. “The performance of the Proteograph Product Suite in customers’ hands has exceeded our expectations, and I am excited about the early data they are generating. This strong progress further substantiates our belief that Seer’s technology will open up a new gateway to the proteome and advance our understanding of biology.” Recent Highlights...

Secured up to $100 million of additional development funding through a non-dilutive financing transaction with AbingworthFunds the Phase 3 development program for seladelpar in primary biliary cholangitis (PBC), including the Phase 3 RESPONSE clinical trialActively recruiting patients in two global, clinical studies evaluating seladelpar in PBCRESPONSE, a 52-week, randomized, placebo-controlled, Phase 3 registrational study ASSURE, an open-label, long-term studyConference call and webcast today at 4:30 p.m. ET NEWARK, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the second quarter ended June...

BURLINGAME, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the second quarter ended June 30, 2021 and provided clinical development and operational highlights. “We are pleased to report on the substantial progress we made since the prior quarter with our lead product candidate, ALX148, and that the United States Adopted Names (USAN) Council has approved ‘evorpacept’ as the nonproprietary (generic) name for ALX148,” said Jaume Pons, Ph.D., Founder, President and Chief Executive Officer of ALX Oncology. “Our highlights include the presentation of additional positive Phase 1b data in second-line or greater HER2 positive gastric or gastroesophageal...

Bottom Line: Q2 2021 Net Income of $141,000 versus Q2 2020 Net Loss of ($766,000) PORTLAND, Maine, Aug. 12, 2021 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2021. Product Sales Results:During the three-month period ended June 30, 2021, total product sales increased by 53%, or $1.6 million, to $4.5 million versus the three-month period ended June 30, 2020. During the six-month period ended June 30, 2021, total product sales increased by 10%, or $773,000, to $8.6 million versus the six-month period ended June 30, 2020. During the...

Call scheduled for today, August 12, at 4:30pm ET TUCSON, Ariz., Aug. 12, 2021 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the quarter ended June 30, 2021. Recent Business HighlightsTotal revenue increased by approximately 45% from the first quarter to the second quarter of 2021.Commercially launched the HTG Transcriptome Panel for sale in the U.S. and Europe in kit form or as a service in HTG’s VERI/O laboratory. The HTG Transcriptome Panel, designed to measure approximately 20,000 mRNA targets using the HTG EdgeSeq technology, is currently available for use with the Illumina sequencing platforms. Through its work with Early Adopter Program collaborators in the first half of 2021, the...

Achieved operational readiness of state-of-the-art LyFE manufacturing facility to support multiple clinical trials Cash, cash equivalents and marketable securities of $974.8 million as of June 30, 2021 includes $391.8 million in net proceeds from initial public offeringSOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today reported financial results for the second quarter and first six months of 2021 and provided business highlights. “Lyell is steadily progressing our two T cell reprogramming platforms, Gen-R and Epi-R, to address what we believe are the primary barriers that limit consistent, reliable and curative responses to cell therapy in solid tumors,” said...

MADISON, Wis., Aug. 12, 2021 (GLOBE NEWSWIRE) — Sonic Foundry, Inc. (OTC Pink Sheets: SOFO), the trusted leader for video creation, management solutions as well as virtual and hybrid events, today announced consolidated financial results for its fiscal 2021 third quarter ended June 30, 2021. Fiscal 2021 Third Quarter HighlightsTotal revenues of $8.7 million, 9 percent increase compared to the $7.9 million revenue in the third quarter of 2020. Gross margin was $6.0 million, or 70 percent of sales, compared to $5.7 million, or 73 percent of sales, in the third quarter of 2020. Net income attributable to common stockholders of $2.6 million, comprised of $2.3 million from forgiveness of the Payroll Protection Program loan, and $0.3 million from operations. Net income per share was $0.33, compared to net income of $107 thousand, or...

Announced FDA clearance of Investigational New Drug application (IND) for lanraplenib (LANRA) for treatment of patients with acute myeloid leukemia (AML) Unveiled SYK portfolio strategy and highlighted momentum of CDK9 inhibitor and discovery programs at virtual R&D Day $419.3 million in cash, cash equivalents and investments as of June 30, 2021 SAN MATEO, Calif., and CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and second quarter financial results. “At our virtual R&D Day in May, we outlined our vision for expanding and driving progress in our pipeline of clinical programs that target dysregulated transcription factors and the regulatory networks within cancerous cells....

New patient Customer Acquisition Cost (CAC) decreased 8% sequentially, while new patient acquisitions per day for comparable brands increased 11% Revenue increased to a record $22.3 million, up 145% from the same year-ago period 93% of Q2 2021 revenue generated by subscriptions, up from 56% in the same year-ago period Platform Contribution of $16.5 million, 74% of net revenue, up 145% from the same year-ago period Total telehealth order volume grew 155% to 199,764NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) — LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the second quarter ended June 30, 2021. All figure comparisons are to the same year-ago quarter unless otherwise noted. Management will host a conference call today at 4:30 p.m. Eastern time to discuss the results. Q2 Financial...

PHOENIX, Aug. 12, 2021 (GLOBE NEWSWIRE) — Mobivity Holdings Corp. (OTCQB:MFON), maker of the award-winning Recurrency platform that increases customer engagement through mobile messaging and personalized digital offers, and drives digital transformation for brands, today announced financial results for the second quarter (“Q2”) ending June 30, 2021. Summary of Fiscal 2021 Second QuarterRevenues of $2.80 million in Q2 2021 compared to $2.77 million in Q2 2020. Gross margin of 55% compared to 56% in Q2 2020. Operating expenses increased to $2.9 million compared to $2.2 million during the same period reported in 2020. Cash and cash equivalents totalled $1.9 million compared to $1.0 million in Q2 of 2020. Net loss was $1.4 million compared to a net loss of $725,000 in Q2 2020.Second Quarter 2021 Business HighlightsExpanded customer...